Linagliptine Intas (Linagliptin)

• Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.
• Type 2 diabetes mellitus: improves glycemic control by increasing insulin secretion and decreasing glucagon release in a glucose‑dependent manner.
• Adjunct to metformin therapy: provides additional HbA1c reduction when metformin alone does not achieve target levels.
• Combination with other oral antidiabetics: enhances overall glucose lowering when used with sulfonylureas, SGLT2 inhibitors, or thiazolidinediones.

• Linagliptin selectively binds to the active site of the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the enzymatic degradation of endogenous incretin hormones such as glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, resulting in lowered post‑prandial and fasting plasma glucose concentrations.

Linagliptine Intas may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nasopharyngitis: mild inflammation of the nose and throat.
• Headache: transient cranial pain.
• Dizziness: sensation of light‑headedness.
• Diarrhea: loose stools.
• Upper respiratory tract infection: cough or congestion.
• Back pain: musculoskeletal discomfort.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain with elevated enzymes.
• Severe allergic reactions: angioedema or anaphylaxis.
• Stevens‑Johnson syndrome: extensive skin blistering.
• Hepatic injury: marked elevation of liver enzymes.
• Hypoglycemia (when combined with insulin or sulfonylureas): symptomatic low blood glucose.

• When prescribing Linagliptine Intas, clinicians should consider several precautionary measures to ensure safe use.
• Renal impairment: no dose adjustment required, but monitor renal function regularly.
• Hepatic impairment: use with caution in patients with moderate liver disease; monitor liver enzymes.
• Concomitant hypoglycemic agents: risk of hypoglycemia increases when combined with insulin or sulfonylureas; adjust dose accordingly.
• Pregnancy and lactation: safety not established; avoid use unless potential benefit justifies risk.
• Elderly patients: assess for frailty and comorbidities, as they may be more susceptible to adverse effects.
• Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight in the original packaging.

Linagliptine Intas can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce linagliptin plasma concentrations and diminish glucose‑lowering effect.

Moderate Interactions (Monitor Closely)

• Insulin or sulfonylureas: additive glucose‑lowering effect may cause hypoglycemia; monitor blood glucose and adjust doses.
• Digoxin: linagliptin may increase digoxin levels; check serum concentrations.
• Diuretics (e.g., thiazides): may enhance risk of dehydration; observe fluid balance.
• Antihypertensives: possible additive blood pressure lowering; monitor hemodynamics.
• Anticoagulants (e.g., warfarin): rare reports of altered INR; periodic coagulation testing advised.